首页> 外文期刊>海南医科大学学报(英文版) >Effect of rosuvastatin intensification therapy on blood lipid metabolism,adipocytokines and plaque stability after PCI in ACS patients
【24h】

Effect of rosuvastatin intensification therapy on blood lipid metabolism,adipocytokines and plaque stability after PCI in ACS patients

机译:瑞舒伐他汀强化治疗对ACS患者PCI术后血脂代谢,脂肪细胞因子和斑块稳定性的影响

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: To explore the effect of rosuvastatin intensification therapy on blood lipid metabolism, adipocytokines and plaque stability after PCI in ACS patients. Methods: ACS patients who received PCI in the hospital between July 2015 and January 2017were reviewed and divided into the routine dose group (n=60) who received rosuvastatin routine dose therapy after PCI and the intensification therapy group (n=46) who received rosuvastatin intensification therapy after PCI. The differences in blood lipid metabolism, adipocytokines and plaque stability were compared between the two groups before and after treatment. Results: Before PCI, the differences in blood lipid metabolism, adipocytokines and plaque stability were not statistically significant between the two groups. 1 month after PCI, lipid metabolism indexes HDL-C and ApoA1 levels in peripheral blood of intensification therapy group were higher than those of routine dose group while LDL-C and ApoB levels were lower than those of routine dose group;adipocytokines APN and Leptin levels in serum were higher than those of routine dose group while Resistin level was lower than that of routine dose group;plaque stability-related indexes ICAM-1, MMP-1 and TIMP-1 levels were lower than those of routine dose group. Conclusion: Rosuvastatin intensification therapy after PCI could effectively regulate the lipid metabolism and increase the plaque stability in ACS patients.
机译:目的:探讨瑞舒伐他汀强化治疗对ACS患者PCI术后血脂代谢,脂肪细胞因子和斑块稳定性的影响。方法:回顾性分析2015年7月至2017年1月在医院接受PCI的ACS患者,分为PCI后接受瑞舒伐他汀常规剂量治疗的常规剂量组(n = 60)和接受瑞舒伐他汀增强治疗组(n = 46)。 PCI后进行强化治疗。比较两组治疗前后血脂代谢,脂肪细胞因子和斑块稳定性的差异。结果:在PCI之前,两组之间的血脂代谢,脂肪细胞因子和斑块稳定性差异无统计学意义。 PCI治疗1个月后,强化治疗组外周血脂质代谢指标HDL-C和ApoA1水平高于常规剂量组,而LDL-C和ApoB水平低于常规剂量组;脂肪细胞因子APN和瘦素水平血清中血脂高于常规剂量组,而抵抗素水平低于常规剂量组;斑块稳定性相关指标ICAM-1,MMP-1和TIMP-1水平低于常规剂量组。结论:PCI后瑞舒伐他汀强化治疗可有效调节ACS患者的脂质代谢,增加斑块稳定性。

著录项

  • 来源
    《海南医科大学学报(英文版)》 |2017年第019期|P.59-62|共4页
  • 作者单位

    [1]Cardiology Department No.2,Jizhong Energy Fengfeng Group Hospital in Fengfeng District Hebei Province,Handan City,Hebei Province,056200;

    [1]Cardiology Department No.2,Jizhong Energy Fengfeng Group Hospital in Fengfeng District Hebei Province,Handan City,Hebei Province,056200;

    [1]Cardiology Department No.2,Jizhong Energy Fengfeng Group Hospital in Fengfeng District Hebei Province,Handan City,Hebei Province,056200;

    [1]Cardiology Department No.2,Jizhong Energy Fengfeng Group Hospital in Fengfeng District Hebei Province,Handan City,Hebei Province,056200;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 CHI
  • 中图分类 内科学;
  • 关键词

    ACS; Rosuvastatin; Blood lipid metabolism; Adipocytokines; Plaque stability;

    机译:ACS;瑞舒伐他汀;血脂代谢;脂肪细胞因子;斑块稳定性;
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号